
Sally Arai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8135385/publications.pdf Version: 2024-02-01



ς αιιν Δραι

#	Article	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 389-401.e1.	2.0	2,636
2	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
3	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood, 2011, 117, 4651-4657.	1.4	319
4	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	30.7	273
5	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 2016, 127, 1656-1665.	1.4	255
6	Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood, 2017, 130, 900-902.	1.4	207
7	methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203), cancet Maematology, the 2019, 6, e132-e143.	4.6	200
8	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood, 2011, 118, 4242-4249.	1.4	196
9	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood, 2009, 114, 1099-1109.	1.4	150
10	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood, 2021, 138, 2278-2289.	1.4	124
11	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 449-455.	2.0	113
12	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood, 2012, 119, 6145-6154.	1.4	107
13	Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm, 2014, 11, 158-162.	0.7	102
14	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood, 2012, 120, 2545-2552.	1.4	101
15	Final results from a defibrotide treatmentâ€ <scp>IND</scp> study for patients with hepatic venoâ€occlusive disease/sinusoidal obstruction syndrome. British Journal of Haematology, 2018, 181, 816-827.	2.5	95
16	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 2021, 5, 143-155.	5.2	92
17	Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. Science Translational Medicine, 2013, 5, 214ra171.	12.4	84
18	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica, 2012, 97, 451-458.	3.5	77

#	Article	IF	CITATIONS
19	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 337-344.	2.0	76
20	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research, 2016, 22, 319-327.	7.0	68
21	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1–2 dose de-escalation study. Lancet Haematology,the, 2015, 2, e367-e375.	4.6	64
22	The Cost of Hematopoietic Stem-Cell Transplantation in the United States. American Health and Drug Benefits, 2017, 10, 366-374.	0.5	62
23	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood, 2017, 130, 360-367.	1.4	52
24	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	1.4	51
25	Assessment of Joint and Fascia Manifestations in Chronic Graftâ€Versusâ€Host Disease. Arthritis and Rheumatology, 2014, 66, 1044-1052.	5.6	50
26	Donor-derived MDS/AML in families with germline GATA2 mutation. Blood, 2018, 132, 1994-1998.	1.4	48
27	Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC: Heart Failure, 2020, 8, 461-468.	4.1	46
28	Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 2019, 4, .	5.0	46
29	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	7.2	45
30	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood, 2016, 128, 2350-2358.	1.4	43
31	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. Blood Advances, 2021, 5, 4278-4284.	5.2	36
32	Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Advances, 2020, 4, 458-466.	5.2	35
33	A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. JACC: Heart Failure, 2019, 7, 958-966.	4.1	31
34	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. Haematologica, 2014, 99, 1618-1623.	3.5	29
35	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica, 2015, 100, 690-695.	3.5	29
36	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 4465-4475.	5.2	28

#	Article	IF	CITATIONS
37	Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Advances, 2018, 2, 681-690.	5.2	27
38	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. Blood Advances, 2018, 2, 1882-1888.	5.2	27
39	Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. Blood Advances, 2020, 4, 815-818.	5.2	27
40	Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 2020, 4, 4474-4482.	5.2	25
41	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 393-399.	2.0	24
42	Natural killer cells: can they be useful as adoptive immunotherapy for cancer?. Expert Opinion on Biological Therapy, 2005, 5, 163-172.	3.1	23
43	Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology, 2018, 154, 728.	4.1	23
44	Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 2021, 5, 3147-3151.	5.2	21
45	Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2010, 16, 1145-1154.	2.0	19
46	Total Lymphoid Irradiation–Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2014, 20, 837-843.	2.0	18
47	A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. Transplantation and Cellular Therapy, 2021, 27, 932.e1-932.e11.	1.2	18
48	Anti–Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 373-380.	2.0	15
49	Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS). Blood, 2014, 124, 2544-2544.	1.4	15
50	Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. Blood Advances, 2022, 6, 2707-2721.	5.2	14
51	Validation of the Hematopoietic Cell Transplantation–Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1744-1748.	2.0	12
52	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 2019, 3, 2454-2464.	5.2	12
53	Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control Blood, 2009, 114, 654-654.	1.4	12
54	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). Blood, 2020, 136, 45-46.	1.4	11

#	Article	IF	CITATIONS
55	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transplantation and Cellular Therapy, 2022, 28, 215.e1-215.e10.	1.2	11
56	Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation, 2020, 26, e328-e332.	2.0	10
57	Grading cardiac response in <scp>AL</scp> amyloidosis: implications for relapse and survival. British Journal of Haematology, 2019, 186, 144-146.	2.5	9
58	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation, 2021, 56, 2664-2671.	2.4	9
59	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 2017, 1, 1347-1357.	5.2	8
60	Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1727-1732.	2.0	8
61	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation, 2021, 56, 368-375.	2.4	8
62	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Advances, 2021, 5, 4549-4559.	5.2	8
63	Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol. Blood, 2013, 122, 700-700.	1.4	8
64	Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab. Blood, 2016, 128, 4525-4525.	1.4	8
65	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 2012, 120, 3701-3701.	1.4	7
66	Rituximab in hematopoietic cell transplantation. Expert Opinion on Biological Therapy, 2010, 10, 971-982.	3.1	5
67	Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy, 2021, 27, 590.e1-590.e8.	1.2	5
68	Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 405.e1-405.e6.	1.2	4
69	A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab. Blood, 2018, 132, 4976-4976.	1.4	4
70	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. Blood, 2020, 136, 47-48.	1.4	4
71	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2019, 134, 2022-2022.	1.4	4
72	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. Blood, 2021, 138, 741-741.	1.4	4

#	Article	IF	CITATIONS
73	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. Blood, 2020, 136, 32-33.	1.4	4
74	CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Blood, 2020, 136, 28-29.	1.4	3
75	Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma Journal of Clinical Oncology, 2016, 34, 8026-8026.	1.6	3
76	Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity Blood, 2006, 108, 603-603.	1.4	3
77	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. Blood, 2021, 138, 878-878.	1.4	3
78	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy, 2022, , .	1.2	3
79	Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study. Blood, 2020, 136, 22-23.	1.4	2
80	Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd. Blood, 2008, 112, 466-466.	1.4	2
81	Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. Blood, 2021, 138, 3885-3885.	1.4	2
82	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. Blood, 2021, 138, 98-98.	1.4	2
83	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation, 2015, 50, 1004-1006.	2.4	1
84	Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation Blood, 2006, 108, 412-412.	1.4	1
85	Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist Blood, 2008, 112, 2234-2234.	1.4	1
86	Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research. Blood, 2013, 122, 3309-3309.	1.4	1
87	Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. Blood, 2015, 126, 3232-3232.	1.4	1
88	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. Blood, 2015, 126, 737-737.	1.4	1
89	Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies. Blood, 2008, 112, 4383-4383.	1.4	0
90	Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation. Blood, 2008, 112, 4348-4348.	1.4	0

#	Article	IF	CITATIONS
91	Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma Blood, 2008, 112, 2194-2194.	1.4	0
92	AL Amyloidosis: Prognosis of Cardiac Involvement Reconsidered Blood, 2009, 114, 4872-4872.	1.4	0
93	Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD) Blood, 2009, 114, 2256-2256.	1.4	0
94	A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis Blood, 2009, 114, 3304-3304.	1.4	0
95	AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions. Blood, 2010, 116, 4044-4044.	1.4	0
96	Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development. Blood, 2010, 116, 2320-2320.	1.4	0
97	A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results. Blood, 2010, 116, 1946-1946.	1.4	0
98	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. Blood, 2011, 118, 3009-3009.	1.4	0
99	A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. Blood, 2011, 118, 1986-1986.	1.4	0
100	Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms Blood, 2012, 120, 3087-3087.	1.4	0
101	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. Blood, 2012, 120, 464-464.	1.4	0
102	Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium. Blood, 2013, 122, 4614-4614.	1.4	0
103	Use of High-Throughput Sequencing (HTS) of TCRß to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant. Blood, 2014, 124, 2473-2473.	1.4	0
104	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease. Blood, 2014, 124, 2470-2470.	1.4	0
105	Costs of Hematopoietic Stem Cell Transplantation and Associated Conditioning Regimens. Blood, 2015, 126, 3270-3270.	1.4	0
106	Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation Journal of Clinical Oncology, 2016, 34, 7046-7046.	1.6	0
107	Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis. Blood, 2018, 132, 4486-4486.	1.4	0
108	<i>Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease</i> . Blood, 2021, 138, 644-644.	1.4	0

#	Article	IF	CITATIONS
109	Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation. Blood, 2020, 136, 33-34.	1.4	0
110	Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis. Blood, 2020, 136, 48-49.	1.4	0
111	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. Blood, 2020, 136, 11-12.	1.4	0
112	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. Blood, 2020, 136, 22-23.	1.4	0